Tenecteplase: Clinical Trials

65 trials of Tenecteplase, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

27 completed, 19 recruiting, 8 not yet recruiting, 7 terminated. 65 Phase 3, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 365Completed 27, Recruiting 19, Not yet recruiting 8, Terminated 7, Unknown 3, Withdrawn 1
Phase 28Completed 4, Recruiting 2, Terminated 1, Withdrawn 1

Follow Tenecteplase: new trials by email Literature Review of Tenecteplase trials Research Report on Tenecteplase

Trials (filtered) newest first · largest first

All 65 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours
Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg) - Acute Ischemic Stroke, Large Vessel Occlusion
Phase 3Not yet recruitingFujian Medical University Union Hospital12662027-04-012026-11-03
INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Mechanical Endovascular Thrombectomy, Intravenous Thrombolysis, Tenecteplase/Alteplase- depending upon availability at each treating centre - Stroke, Acute Ischemic, Medium Vessel Occlusion
Phase 3Not yet recruitingUniversity of Calgary8002026-12-152026-10-30
Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours
Tenecteplase, Endovascular Treatment - Medium Vessel Occlusion Stroke (MeVO), Acute Ischemic Stroke
Phase 3Not yet recruitingThe First Affiliated Hospital of University of Science and Technology of China13952026-12-012026-11-12
Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events
rhTNK-tPA (0.25mg/kg), Reteplase 10 Units (U) plus a second dose of reteplase 10 U, No thrombolysis (thrombectomy alone) - Acute Ischemic Stroke, Large Vessel Occlusion
Phase 3RecruitingYongjun Wang14402026-10-162026-10-22
Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment - Acute Ischemic Stroke, Tenecteplase
Phase 3RecruitingFirst Affiliated Hospital of Guangxi Medical University3522026-09-242026-09-30
Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion
Recombinant Tissue Plasminogen Activator (rt-PA), Intra-arterial Thrombolysis, Best Medical Management - Medium Vessel Occlusion, Ischemic Stroke, Acute
Phase 3RecruitingThe First Affiliated Hospital with Nanjing Medical University3722026-09-192026-09-23
ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Tenecteplase or Alteplase- depending upon availability at each treating centre, Control - Stroke, Acute Ischemic, Endovascular Thrombectomy
Phase 3RecruitingUniversity of Calgary15002026-08-112026-10-21
rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window
Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment - Acute Ischemic Stroke
Phase 3RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University7502026-08-012026-06-15
Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage
Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined with Tenecteplase, Standard medical treatment - Intracerebral Hemorrhage Lobar
Phase 3Not yet recruitingBeijing Tiantan Hospital6362026-03-312026-03-25
Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy
Tenecteplase (0.0938mg/kg), Placebo - Stroke
Phase 3Not yet recruitingChuansheng Zhao3442026-03-012026-03-13
Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window
Tenecteplase (0.25mg/kg), Standard Medical Management - Stroke
Phase 3Not yet recruitingFirst Hospital of China Medical University8642026-03-012026-03-17
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
Tenecteplase, Standard of care treatment - Acute Ischemic Stroke
Phase 3RecruitingBoehringer Ingelheim13252026-02-172026-11-10
Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) - Acute Ischemic Stroke, Large Vessel Occlusion
Phase 3RecruitingXuanwu Hospital, Beijing5722026-01-062026-08-19
Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke
Tenecteplase, Alteplase - Stroke, Ischemic, Stroke, Acute
Phase 3RecruitingXuanwu Hospital, Beijing8502025-12-252026-04-09
Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT
TNK, Standard medical treatment - Acute Ischemic Stroke, Large Vessel Occlusion
Phase 3Not yet recruitingThe First Affiliated Hospital of University of Science and Technology of China7942025-11-012025-09-11
Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment - Stroke Ischemic
Phase 3Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine3302025-09-012025-08-15
Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg), Placebo - Acute Ischemic Stroke
Phase 3RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University9122025-08-142025-12-16
Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke
Tenecteplase (0.25mg/kg), Standard medical treatment - Stroke, Ischemic, Medium Vessel Occlusions
Phase 3RecruitingBeijing Tiantan Hospital5962025-07-302026-04-01
Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial
tenecteplase - Ischemic Stroke, Acute Disease
Phase 2 / Phase 3RecruitingProMedica Health System1322025-07-302026-01-21
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND
Tenecteplase (0.25mg/kg), Standard medical treatment - Stroke
Phase 3RecruitingBeijing Tiantan Hospital3302025-05-302026-04-01

Showing 20 of 65. Sign in to see all of them.

Conditions studied

Ischemic Stroke (39)  ·  Stroke (19)  ·  Myocardial Infarction (6)  ·  ST Elevation Myocardial Infarction (3)  ·  Cerebrovascular Disorders (2)  ·  Hemorrhage (2)  ·  Intracranial Thrombosis (2)  ·  Pulmonary Embolism (2)  ·  Retinal Artery Occlusion (2)  ·  Acute Disease (1)  ·  Brain Diseases (1)  ·  Brain Infarction (1)  ·  Cardiovascular Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Cerebral Infarction (1)

Sponsors

Beijing Tiantan Hospital (8)  ·  Boehringer Ingelheim (5)  ·  Genentech, Inc. (5)  ·  The First Affiliated Hospital of University of Science and Technology of China (5)  ·  University of Calgary (5)  ·  General Hospital of Shenyang Military Region (3)  ·  Hospital Moinhos de Vento (2)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2)  ·  University of Melbourne (2)  ·  Xuanwu Hospital, Beijing (2)  ·  AO GENERIUM (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Chuansheng Zhao (1)  ·  First Affiliated Hospital of Guangxi Medical University (1)  ·  First Hospital of China Medical University (1)

Countries

China (29)  ·  Canada (8)  ·  Norway (8)  ·  Australia (7)  ·  Spain (6)  ·  United States (6)  ·  Austria (5)  ·  Belgium (5)  ·  Brazil (5)  ·  Germany (5)  ·  Finland (4)  ·  France (4)  ·  Sweden (4)  ·  United Kingdom (4)  ·  Denmark (3)

Top investigators

Bijoy K Menon, MD (3)  ·  Raul G Nogueira, MD (3)  ·  Barbara Gillespie, M.D., FASN (2)  ·  Craig Anderson, MD (2)  ·  Sheila CO Martins, MD, PhD (2)  ·  Wei Hu, MD (2)  ·  Yong Cao (2)  ·  Andy Yong, MBBS (1)  ·  Anthony Keech, MBBS (1)  ·  Barbara Gillespie, MD, FASN (1)  ·  Bijoy K Menon, MD, MSc (1)  ·  Bruce Campbell (1)  ·  Bruce Campbell, MD, PhD (1)

Results publications

PMID 26387127, PMID 33857326, PMID 37830342, PMID 15262836, PMID 19092151, PMID 20133491, PMID 20598969, PMID 21111365, PMID 21315210, PMID 22172434, PMID 23473396, PMID 24716681, PMID 24916050, PMID 25161043, PMID 25433511, PMID 25691510, PMID 26304934, PMID 26783237, PMID 28335835, PMID 28525886, PMID 28780236, PMID 30602354, PMID 31009339, PMID 32511749, PMID 32631157, PMID 33446083, PMID 33464335, PMID 34564893, PMID 35262424, PMID 35369714, PMID 35525250, PMID 35590386, PMID 35779553, PMID 36549308, PMID 37247876, PMID 37800372, PMID 38124230, PMID 38174568, PMID 38275116, PMID 38329148, PMID 38676572, PMID 38768626, PMID 38884324, PMID 39264623, PMID 39379314, PMID 39424558, PMID 39435713, PMID 39567366, PMID 39654273, PMID 39689189

NIH funding

2018 (2), 2014 (1), 2023 (1), 2025 (1)